Evidence map›Paper›PMID 39801987›Full record

ArticleHeliyon2025

Márk Kovács-Valasek, Csaba Fekete, Andrea Kovács-Valasek

Abstract read
In one paragraph

Article in Heliyon, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Márk Kovács-ValasekPannonPharma Pharmaceutical Ltd., H-7720, Pécsvárad, Hungary.
Csaba FeketeInstitute of Biology, Faculty of Sciences, University of Pécs, H-7624, Pécs, Hungary.
Andrea Kovács-ValasekInstitute of Biology, Faculty of Sciences, University of Pécs, H-7624, Pécs, Hungary.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In the global effort to discover or design new effective antibiotics to fight infectious diseases, the increasingly available multi-omics data with novel bioinformatics tools open up new horizons for the exploration of the genetic potential of bacteria to synthesize bioactive secondary metabolites. Rare actinomycetes are a prolific source of structurally diverse secondary metabolites that exhibit remarkable clinical and industrial importance. Recently several excellent genome mining tools have been available for identifying biosynthetic gene clusters, however in cases of poor-quality sequences and inappropriate genome assembly, these tools are not always able to identify the corresponding gene clusters. In this context, based on the previously characterized primycin biosynthetic gene cluster (PBGC) of the

Indexed as

Primycin biosynthetic gene cluster - PseudonocardiaceaeStructural genomics

Identifiers

PMID39801987
PMCPMC11721240

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.